广东省深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 28 层 2803-04 室 邮编：518048 电话：（86-755）2939-5288 传真：（86-755）2939-5289 junhesz@junhe.com 北京市君合（深圳）律师事务所 关于深圳华大智造科技股份有限公司 二〇二五年第四次临时股东大会的法律意见书 致：深圳华大智造科技股份有限公司 北京市君合（深圳）律师事务所（以下简称"本所"）接受深圳华大智造科技 股份有限公司（以下简称"贵公司"）的委托，就贵公司二〇二五年第四次临时股 东大会（以下简称"本次股东大会"）召开的有关事宜，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、中国证券监督管理委员会颁布的《上市公司股东 会规则》（以下简称"《股东会规则》"）等中华人民共和国（以下简称"中国"，仅 为出具本法律意见书之目的，不包括中国香港特别行政区、中国澳门特别行政区 及中国台湾省）现行法律、法规、规章、规范性文件（以下合称"法律、法规"） 以及现行《深圳华大智造科技股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，出具本法律意见书。 本法律意见书仅就本次股东大 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-071 深圳华大智造科技股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 注：截至本次股东大会股权登记日（2025 年 10 月 20 日）的总股本为 416,516,155 股。其中， 公司回购专用账户持有股份数为 3,987,952 股，不享有股东大会表决权。 （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由董事会召集，董事长汪建先生因公未能现场出席会议，经全 体董事一致推举，由董事余德健先生主持，会议以现场及网络方式投票表决，本 次股东大会的召集和召开程序、出席会议人员的资格和召集人资格、会议的表决 程序均符合《公司法》及《公司章程》的规定。 （五） 公司董事、监事和董事会秘书的出席情况 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 28 日 （二） 股东大会召开的地点：深圳市盐田区梅沙街道云华 ...

董秘回答(华大智造SH688114)： 尊敬的投资者，您好！ 为了使公司全体股东能够公平获取股东户数信息，公司会在定期报告中按照中 国证监会、上交所相关要求对股东户数信息在指定媒体上进行披露，敬请关注公司定期报告。截至2025 年9月末的公司股东总户数已在公司《2025年三季度报告》中披露。 感谢您的关注！查看更多董秘问答 >> 免责声明：本信息由新浪财经从公开信息中摘录，不构成任何投资建议；新浪财经不保证数据的准确 性，内容仅供参考。 投资者提问： 华大智造股东数量 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.869 billion yuan for the first three quarters of 2025, showing a year-over-year decrease of 0.01%, while the net profit attributable to the parent company was -120 million yuan, an increase of 74.20% year-over-year [4][5] - In Q3 2025, the company achieved a revenue of 755 million yuan, representing a year-over-year growth of 14.45%, and a net profit of -16 million yuan, up 90.31% year-over-year [5] - The revenue growth in Q3 2025 is attributed to the shift of domestic customers' data platforms and increased installation and usage of related reagents due to Illumina being listed as an unreliable entity by the Ministry of Commerce [5][6] Financial Performance - The company’s revenue for Q1, Q2, and Q3 of 2025 was 455 million yuan (down 14.26% year-over-year), 659 million yuan (down 2.93% year-over-year), and 755 million yuan (up 14.45% year-over-year) respectively [5] - The company’s expense ratios for sales, management, and R&D in Q3 2025 were 23.19%, 11.19%, and 14.80%, respectively, showing significant reductions both year-over-year and quarter-over-quarter [5] - The company has entered a new phase of globalization by licensing its sequencing technology to Swiss Rockets, with an initial payment of 20 million USD and milestone payments totaling at least 120 million USD [6] Revenue and Profit Forecast - The company is expected to achieve revenues of 2.824 billion yuan, 3.341 billion yuan, and 3.943 billion yuan for the years 2025, 2026, and 2027, with year-over-year growth rates of -6.3%, 18.3%, and 18.0% respectively [7] - The net profit attributable to the parent company is projected to be -98 million yuan, 160 million yuan, and 382 million yuan for the years 2025, 2026, and 2027, with year-over-year growth rates of 83.6%, 262.9%, and 138.6% respectively [7][10]

Core Insights - BGI Genomics reported a revenue of 1.869 billion yuan for the first nine months of the year, a slight decrease of 0.01% compared to the same period last year [1] - The company incurred a net loss of 120 million yuan for the first nine months, with a non-recurring net loss of 228 million yuan [1] - As of the end of Q3, the net cash flow from operating activities was -289 million yuan [1] Financial Performance - In Q3, BGI Genomics achieved a revenue of 755 million yuan, representing a year-on-year growth of 14.45% [1] - The net loss for Q3 was 16 million yuan, with a non-recurring net loss of 25.39 million yuan [1] - The latest gross margin was 53.32%, down 5.81 percentage points from the same period last year [1] - The latest debt-to-asset ratio was 23.69%, an increase of 4.06 percentage points compared to the same period last year [1] Research and Development - The company reduced its R&D expenditure to 447 million yuan in the first three quarters, a decrease of 24.25% year-on-year [1] - R&D spending accounted for 23.94% of total revenue, down 7.66 percentage points year-on-year [1] - BGI Genomics stated that it is focusing on cost reduction and efficiency improvement, leading to a decrease in R&D investment [1] Ownership Structure - As of September 30, 2025, major shareholders include Shenzhen BGI Technology Holdings Group Co., Ltd. with 36.73% ownership, and other investors with smaller stakes [2] - CPE Investment reduced its stake by 0.59 percentage points in Q3 2025 compared to the previous half-year report [2]

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. reported a significant improvement in its financial performance for the third quarter of 2025, with a notable increase in revenue and a reduction in costs, leading to a substantial decrease in losses compared to the previous year [2][11]. Financial Data Summary - The total operating revenue for the first three quarters of 2025 was approximately CNY 1.87 billion, a slight decrease of 0.008% compared to CNY 1.87 billion in the same period of 2024 [22]. - The total operating costs decreased to approximately CNY 1.99 billion, down from CNY 2.30 billion in the previous year, marking a reduction of about 13.14% [22]. - The net loss for the first three quarters of 2025 was approximately CNY 121 million, a significant improvement compared to a net loss of approximately CNY 467 million in the same period of 2024, representing a reduction in losses of about 74.20% [23]. Non-Recurring Gains and Losses - The company reported non-recurring gains and losses totaling approximately CNY 9.39 million for the current period, compared to CNY 108.44 million in the previous year [9]. - The adjustments included the reversal of tax provisions related to previous years' tax disputes, which positively impacted the financial results [9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,418, with the top ten shareholders holding significant stakes, including Shenzhen BGI Technology Holdings Group Co., Ltd. with 36.73% [12][14]. - The company’s major shareholders are closely associated with the actual controller, Wang Jian [15]. Cash Flow Analysis - The net cash flow from operating activities for the first three quarters of 2025 was negative CNY 288.73 million, an improvement from negative CNY 850.49 million in the same period of 2024, indicating better cash collection from sales [27]. - The net cash flow from investing activities was negative CNY 140.86 million, compared to negative CNY 387.28 million in the previous year [27]. - The net cash flow from financing activities was positive CNY 240.77 million, contrasting with a negative cash flow of CNY 24.81 million in the same period of 2024 [27].

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Insights - The company reported a revenue of 1.869 billion RMB for the first nine months of 2025, showing a year-on-year stability, while the net loss was reduced significantly by 74.2% and 54.2% for the net loss attributable to the parent and the adjusted net loss respectively [1] - The company is expected to benefit from the domestic gene sequencing business due to the resonance of market demand and government restrictions, while overseas business is anticipated to achieve breakthroughs through licensing and diversified layouts [1] - The gross margin for the main business was 53.3%, down 8.2 percentage points year-on-year, primarily due to intensified industry competition [2] - The company has entered into a licensing agreement for its CoolMPS sequencing technology, which is expected to accelerate its global strategy and enhance its market presence [3] - New product launches, including the DNBSEQ-T7+ and DNBSEQ-T1+, are expected to drive growth in sequencing reagent consumption [4] - Revenue forecasts for 2025-2027 have been adjusted downwards to 2.92 billion, 3.60 billion, and 4.10 billion RMB respectively, reflecting a 7%, 6%, and 6% decrease compared to previous estimates [5] Summary by Sections Financial Performance - For the first nine months of 2025, the company achieved a revenue of 1.869 billion RMB, with a significant reduction in net losses [1] - The gross margin for the main business was reported at 53.3%, a decline attributed to competitive pricing strategies [2] Strategic Developments - The company has licensed its CoolMPS sequencing technology to Swiss Rockets, with total payments expected to exceed 120 million USD, which will aid in global market expansion [3] - The introduction of innovative products is expected to enhance the company's competitive edge in the high-throughput sequencing market [4] Earnings Forecast - The revised revenue projections for 2025-2027 are 29.2 billion, 36.0 billion, and 41.0 billion RMB, with corresponding net profits of 0.85 billion, 3.07 billion, and 3.94 billion RMB [5]

Core Insights - Shenzhen BGI Genomics Co., Ltd. reported a slight decline in revenue for the first three quarters of 2025, with total revenue at 1.87 billion yuan, a year-on-year decrease of 0.01% [1] - The company reduced its net loss from 463 million yuan in the same period last year to 120 million yuan, indicating an improvement in financial performance [1] - Research and development expenses amounted to 123 million yuan, representing 16.27% of total revenue, which is a decrease compared to the same period last year [1] Financial Performance - For Q3 2025, the company achieved revenue of 755 million yuan, a year-on-year increase of 14.5% [1] - The net loss for Q3 decreased from 165 million yuan to 16 million yuan, showing a significant reduction in losses [1] - The adjusted net loss also improved from 173 million yuan to 25.39 million yuan in Q3 [1] Operational Strategy - The company emphasized its strategy of cost reduction and efficiency improvement, focusing on core projects to optimize resource allocation [1]

Core Viewpoint - Recent rumors suggested that BGI Genomics is venturing into car manufacturing, which the company clarified is not the case. Instead, it focuses on using vehicles as mobile platforms for various healthcare and scientific applications [2]. Group 1: Company Clarification - BGI Genomics emphasized that it is not "manufacturing cars" but rather utilizing vehicles for mobile platforms, including automated ultrasound vehicles and mobile testing units [2]. - The company has made significant contributions in areas such as public health and medical resource distribution through its mobile platforms [2]. - BGI Genomics maintains a clear focus on its core business, prioritizing the development and manufacturing of life science tools while adhering to principles of technological synergy and scenario extension for new business ventures [2]. Group 2: Business Overview - Established in 2016, BGI Genomics is dedicated to advancing research and clinical applications through core technologies in gene sequencing and multi-omics [3]. - The company has a global presence, with operations in over 110 countries and regions, nine R&D centers, seven production bases, and 13 customer experience centers as of June 30, 2025 [2]. - BGI Genomics serves over 3,560 users worldwide, highlighting its extensive reach and impact in the life sciences sector [2].